Table 2. Genes with differential expressions grouped into potentially relevant functional classes of biologic activity^a.

Signal pathway	Deferentially expressed genes with 2-fold or greater change
DNA damage	DDIT4, MYH9, TP53INP1, TP53INP2, HECTD1, SMG1, VCPIP1, MDM4, HIPK2, ATM, UBE2N, RAD51, RAD51AP1, RAD51C, PBK, MSH2, MRP63, KCTD6, PSMG1, DUSP12, TP53TG1
Cell cycle	USP53, MAP4, GPNMB, PLK1S1, TGFβ1, ATRX, HDAC9, SMEK2, FOXK1, MYCBP2, CDKN1A, BCCIP, CCNE2, ID1, ID3, CDK1, CDK2, CDK4, CDK5, CDKN2C, CDKN3, CDC25A, MOSC1, SKP2, PCNA, PKMYT1, PLK4, ANAPC10, ANAPC11, ANAPC13, ANAPC16, GADD45GIPI, ARF3
Cell apoptosis	CASP4, TMBIM1, ITPRIPL2, XIAP, GSK3B, RASA2, RASA4, CREB5, PARP8, MCL1, ULK1, PTEN, MRAS, JAK1, ANTXR1, BCL2L12, HSP90AA1, BID, PARP2, ATG12
Translational control	PPP1R13L, PPP1R9A, PPPRARA, EEF2K, EEF1B2, PABPC1L, EEF1A1, EIF2C2, EIF5A2, EIF5B, EIF2AK2, EIF2AK4, EIF1AX, EEF1E1, EIF2B2, EIF4E, EIF4E2, EIF3K, EIF2S1
Cellular metabolism	GRB10, EHBP1, MEF2A, MEF2D, PKM2, UCP2, VDAC3, SHCBP1

^aRegular and boldface italic font respectively indicate significantly higher and lower expressed genes in both GO treatment groups (10 μg/mL and 100 μg/mL), compared to the control group.